Abstract
Hypogonadism affects 4-5 million males in the United States (US), and is associated with a number of important health problems, including obesity, metabolic syndrome, type 2 diabetes mellitus, and increased cardiovascular risk. Patients are typically treated using testosterone therapy (TTh), including long-acting testosterone undecanoate (TU) and short-acting injectables like testosterone cypionate (TC). Although the efficacy and safety of testosterone injections have been widely studied, the comparative advantages of long-acting TU, such as patient compliance and the subsequent potential health benefits, have not been examined in detail.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
